Evidence map›Paper›PMID 41665036›Full record

ArticleActa psychiatrica Scandinavica2025

New Episodes and Suicidal Risks in Bipolar and Major Depressive Disorder Patients During Versus Before Long-Term Treatment With Lithium.

Maurizio Pompili, Isabella Berardelli, Salvatore Sarubbi, Elena Rogante, Mariarosaria Cifrodelli, Denise Erbuto, Dorian A Lamis, Ross J Baldessarini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta psychiatrica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maurizio PompiliDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'andrea Hospital, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-1886-4977
Isabella BerardelliDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'andrea Hospital, Sapienza University of Rome, Rome, Italy.
Salvatore SarubbiDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'andrea Hospital, Sapienza University of Rome, Rome, Italy.
Elena RoganteDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Mariarosaria CifrodelliDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Denise ErbutoDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'andrea Hospital, Sapienza University of Rome, Rome, Italy.
Dorian A LamisDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine/Grady Health Systems, Atlanta, Georgia, USA.
Ross J BaldessariniInternational Consortium for Bipolar & Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA.ORCID 0000-0001-9718-8211

Funding

Bruce J. Anderson FoundationMcLean Private Donors Research Fund (to RJB).Universita degli Studi di Roma La Sapienza CRUI-CARE AGREEMENT
6 · The paper itself

Abstract

objectivesLithium treatment reduces the risk of recurring episodes in bipolar disorder (BD) and probably also in major depressive disorder (MDD) and has evidence of antisuicidal effects. Study objectives were to test for effects of adding lithium treatment for one year to a year of other treatments on risks of illness recurrence, suicidal ideation, and suicide attempts.

methodsWe compared 296 major mood disorder outpatients for 12 months with treatment that did not include lithium versus 12 months with lithium included. We considered differences in the recurrence of new episodes of illness, new suicidal ideation and suicide attempts, and estimated time to these outcomes with survival analyses.

resultsWith lithium treatment included, there were marked reductions in episode recurrences (3.12-fold), suicidal ideation (4.78-fold), and suicide attempts (6.54-fold) in both BD and MDD patients, with corresponding delays to these outcomes.

conclusionsAdding lithium treatment was strongly associated with reduced risk and delay of clinical recurrence, suicidal ideation and suicide attempts in both BD and MDD outpatients.

Indexed as

Antimanic AgentsBipolar DisorderLithium CompoundsMajor Depressive DisorderSuicidal IdeationSuicide, AttemptedAdultAntidepressive AgentsFemaleHumansMaleMiddle AgedRecurrenceTreatment OutcomeAntidepressive AgentsAntimanic AgentsLithium Compoundsbefore vs. during treatmentbipolar disorderlithiumlong‐term treatmentmajor depressive disorder

Identifiers

PMID41665036
PMCPMC12404890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.